ReviewJournal of endocrinological investigation2016
Resistin's, obesity and insulin resistance: the continuing disconnect between rodents and humans.
Review in Journal of endocrinological investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 115 citations in OpenAlex.
- Trial
- Trial
- The Combination of Whey Protein and Dietary Fiber Does Not Alter Low-Grade Inflammation or Adipose Tissue Gene Expression in Adults with Abdominal Obesity.The review of diabetic studies : RDS · 2019Trial
- Examining the interplay between sdLDL, resistin, and BMI.Scientific reports · 2025Article
- SERCA blockade as a treatment strategy for obesity.European journal of applied physiology · 2025Review
- The role of RETN in stomach adenocarcinoma (STAD): insights from pan-cancer analysis of RNA-seq data based on the TCGA database.Discover oncology · 2025Article
- Resistin upregulates fatty acid oxidation in synoviocytes of metabolic syndrome-associated knee osteoarthritis via CAP1/PKA/CREB to promote inflammation and catabolism.Arthritis research & therapy · 2025Article
- Resistin in cardiac diseases: from molecular mechanisms to clinical implications.Frontiers in endocrinology · 2025Review
- Review
- Review
- Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.Current obesity reports · 2024Review
- Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis.Lipids in health and disease · 2024Review
- Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers.Cell communication and signaling : CCS · 2024Review
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease.Frontiers in immunology · 2024Review
- Is there a causal relationship between resistin levels and bone mineral density, fracture occurrence? A mendelian randomization study.PloS one · 2024Article
- Bioinformatics study of the potential therapeutic effects of ginsenoside Rh3 in reversing insulin resistance.Frontiers in molecular biosciences · 2024Article
- Assessing the impact of body composition, metabolic and oxidative stress parameters on insulin resistance as a prognostic marker for reactive hypoglycemia: a cross-sectional study in overweight, obese, and normal weight individuals.Frontiers in pharmacology · 2024Article
- Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines.Aging · 2023Review
- Circulating miRNAs Expression in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.International journal of molecular sciences · 2023Article
- Periodontitis as a promoting factor of T2D: current evidence and mechanisms.International journal of oral science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis review aimed to discuss the conflicting findings from resistin research in rodents and humans as well as recent advances in our understanding of resistin's role in obesity and insulin resistance.
methodsA comprehensive review and synthesis of resistin's role in obesity and insulin resistance as well as conflicting findings from resistin research in rodents and humans.
resultsIn rodents, resistin is increased in high-fat/high-carbohydrate-fed, obese states characterized by impaired glucose uptake and insulin sensitivity. Resistin plays a causative role in the development of insulin resistance in rodents via 5' AMP-activated protein kinase (AMPK)-dependent and AMPK-independent suppressor of cytokine signaling-3 (SOCS-3) signaling. In contrast to rodents, human resistin is primarily secreted by peripheral-blood mononuclear cells (PBMCs) as opposed to white adipocytes. Circulating resistin levels have been positively associated with central/visceral obesity (but not BMI) as well as insulin resistance, while other studies show no such association. Human resistin has a role in pro-inflammatory processes that have been conclusively associated with obesity and insulin resistance. PBMCs, as well as vascular cells, have been identified as the primary targets of resistin's pro-inflammatory activity via nuclear factor-κB (NF-κB, p50/p65) and other signaling pathways.
conclusionMounting evidence reveals a continuing disconnect between resistin's role in rodents and humans due to significant differences between these two species with respect to resistin's gene and protein structure, differential gene regulation, tissue-specific distribution, and insulin resistance induction as well as a paucity of evidence regarding the resistin receptor and downstream signaling mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.